Q-omics provides the consensus-scored LDOC1 profile across patient tissues and cancer cell-line models. LDOC1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LDOC1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LDOC1 RNA expression shows 16,712 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where LDOC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDOC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDOC1 survival associations across molecular data types. LDOC1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDOC1 RNA expression–survival associations across cancer types. High LDOC1 expression shows unfavorable associations in UCEC, KIRP and BLCA, but favorable associations in KIRC, UVM and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for LDOC1 RNA expression.
This table summarizes LDOC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LDOC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDOC1 shows lower tumor expression in KIRC, STAD, COAD and KICH and higher tumor expression in THCA and LUAD. The KIRC box plot shows higher LDOC1 RNA expression in normal versus tumor tissue (log2 FC = −0.668, t-test p < 0.001).
This table shows molecular features associated with LDOC1 in patient tissues and cancer cell lines. In patient samples, LDOC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LDOC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
